Bain leads $150M round to push blindness biotech's rare disease drug toward FDA

Paul Schloesser

Associate Editor

Alkeus Pharmaceuticals has raised $150 million via a Series B round in order to advance a precision medicine candidate to treat Stargardt disease, a currently …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bain leads $150M round to push blindness biotech's rare disease drug toward FDA

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Bain leads $150M round to push blind­ness biotech's rare dis­ease drug to­ward FDA

Associate Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Bain leads $150M round to push blindness biotech's rare disease drug toward FDA